FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
FATE on Nasdaq
Shares outstanding
114,331,829
Price per share
$0.98
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
80,482,515
Total reported value
$101,400,876
% of total 13F portfolios
0%
Share change
+1,171,948
Value change
+$1,893,628
Number of holders
137
Price from insider filings
$0.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 15% 0% $25,118,211 +$174,923 17,941,579 +0.7% Redmile Group, LLC 02 Jul 2025
VANGUARD GROUP INC 7.6% $9,818,776 8,766,764 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 6.9% $10,600,447 7,852,183 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 2% -77% $2,546,902 -$6,958,784 2,274,020 -73% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Schonfeld Strategic Advisors LLC 0.82% -85% $1,050,024 -$7,679,831 937,521 -88% Schonfeld Strategic Advisors LLC 30 Jun 2025
As of 30 Sep 2025, FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 137 institutional shareholders filing 13F forms. They hold 80,482,515 shares. of 114,331,829 outstanding shares (70%) .

Top 25 institutional shareholders own 63% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Redmile Group, LLC 11% 12,872,946 0% 1.6% $16,219,912
BlackRock, Inc. 9.3% 10,680,727 -1.2% 0% $13,457,714
VANGUARD GROUP INC 7.7% 8,798,491 +0.36% 0% $11,086,098
Wilshire Advisors LLC 7.4% 8,486,822 28% $10,693,396
JOHNSON & JOHNSON 3% 3,379,064 0% 0.85% $4,257,621
ACADIAN ASSET MANAGEMENT LLC 2.4% 2,710,234 +10% 0.01% $3,412,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,530,212 +4.2% 0% $3,188,561
Vestal Point Capital, LP 2.2% 2,515,000 0% 0.14% $3,168,900
STATE STREET CORP 2.1% 2,417,135 +8.4% 0% $3,045,590
DIMENSIONAL FUND ADVISORS LP 1.8% 2,094,975 -14% 0% $2,637,886
TANG CAPITAL MANAGEMENT LLC 1.6% 1,867,773 0% 0.09% $2,353,394
GOLDMAN SACHS GROUP INC 1.3% 1,486,407 -41% 0% $1,872,873
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,262,515 +489% 0% $1,590,769
AQR CAPITAL MANAGEMENT LLC 0.99% 1,131,414 +34% 0% $1,425,581
TWO SIGMA ADVISERS, LP 0.88% 1,007,400 +104% 0% $1,269,324
MILLENNIUM MANAGEMENT LLC 0.84% 963,871 +9.6% 0% $1,214,477
MORGAN STANLEY 0.81% 929,944 -62% 0% $1,171,730
TWO SIGMA INVESTMENTS, LP 0.79% 900,757 +294% 0% $1,134,954
CITADEL ADVISORS LLC 0.72% 824,545 -82% 0% $1,038,927
JACOBS LEVY EQUITY MANAGEMENT, INC 0.71% 814,639 -33% 0% $1,026,445
NORTHERN TRUST CORP 0.71% 814,465 -3.5% 0% $1,026,226
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 785,921 +7.1% 0% $990,260
Monaco Asset Management SAM 0.67% 770,000 +14% 0.36% $970,200
Bruce & Co., Inc. 0.64% 729,188 +70% 0.28% $918,777
Woodline Partners LP 0.62% 712,650 0% 0% $897,939

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 223,278 $220,114 +$22,415 $0.98 6
2025 Q3 80,482,515 $101,400,876 +$1,893,628 $1.26 137
2025 Q2 79,555,724 $88,833,451 -$17,593,195 $1.12 136
2025 Q1 96,451,503 $76,210,377 -$16,246,755 $0.79 127
2024 Q4 100,742,490 $166,216,764 -$49,322,737 $1.65 154
2024 Q3 114,626,757 $401,134,107 -$26,268,311 $3.50 157
2024 Q2 122,159,363 $400,671,566 -$37,762,295 $3.28 176
2024 Q1 122,980,750 $902,678,660 +$225,457,297 $7.34 160
2023 Q4 95,368,059 $356,677,597 -$5,241,221 $3.74 152
2023 Q3 95,698,313 $202,876,531 -$41,469,527 $2.12 164
2023 Q2 109,140,532 $519,540,682 -$18,388,551 $4.76 183
2023 Q1 112,556,300 $641,545,712 -$48,046,056 $5.70 177
2022 Q4 105,538,752 $1,064,884,147 -$72,227,908 $10.09 222
2022 Q3 107,847,419 $2,414,270,747 -$51,535,763 $22.41 226
2022 Q2 109,105,314 $2,682,160,938 +$198,082,382 $24.78 212
2022 Q1 101,146,307 $3,918,572,903 +$154,288,770 $38.77 235
2021 Q4 96,474,919 $5,644,897,783 +$10,118,846 $58.51 240
2021 Q3 95,702,027 $5,670,584,893 +$32,917,992 $59.27 254
2021 Q2 94,438,853 $8,194,463,579 +$63,508,082 $86.79 264
2021 Q1 93,763,343 $7,731,987,612 +$546,947,235 $82.45 251
2020 Q4 87,411,381 $7,948,482,716 -$84,784,180 $90.93 247
2020 Q3 87,813,890 $3,509,314,003 +$84,938,020 $39.97 210
2020 Q2 85,944,579 $2,946,905,994 +$357,311,792 $34.31 199
2020 Q1 75,606,763 $1,679,422,294 +$78,833,879 $22.21 153
2019 Q4 72,206,146 $1,413,058,139 -$18,741,577 $19.57 145
2019 Q3 73,759,772 $1,145,458,451 +$162,122,671 $15.53 147
2019 Q2 63,158,854 $1,282,170,068 +$56,656,459 $20.30 133
2019 Q1 60,804,461 $1,068,331,832 +$24,885,328 $17.57 121
2018 Q4 59,421,648 $762,327,973 +$32,572,198 $12.83 120
2018 Q3 54,832,749 $893,221,923 +$193,920,385 $16.29 116
2018 Q2 43,038,652 $488,060,307 +$35,286,017 $11.34 102
2018 Q1 39,404,544 $384,590,041 +$45,054,814 $9.76 87
2017 Q4 35,346,074 $215,961,575 +$67,123,779 $6.11 78
2017 Q3 25,410,496 $100,632,735 -$4,500,070 $3.96 71
2017 Q2 26,610,964 $86,219,950 +$4,849,002 $3.24 57
2017 Q1 25,029,354 $113,880,000 +$9,086,443 $4.55 51
2016 Q4 23,128,984 $57,885,000 +$7,405,875 $2.51 33
2016 Q3 19,481,982 $60,781,000 +$17,053,469 $3.12 36
2016 Q2 14,071,764 $23,921,000 -$3,087,760 $1.70 37
2016 Q1 15,773,542 $28,394,000 -$9,461,086 $1.80 42
2015 Q4 18,614,016 $62,724,000 -$726,308 $3.37 51
2015 Q3 18,349,000 $97,801,000 +$1,748,454 $5.33 41
2015 Q2 18,018,637 $116,577,000 +$48,004,684 $6.47 37
2015 Q1 10,608,782 $51,875,000 +$1,628,433 $4.89 25
2014 Q4 10,275,305 $51,680,000 -$3,435 $5.02 23
2014 Q3 10,270,522 $52,580,000 +$2,082,379 $5.10 22
2014 Q2 9,853,337 $62,410,000 +$1,716,802 $6.31 21
2014 Q1 9,563,610 $92,835,964 +$30,694,357 $9.74 21